A number of studies show that patients with colorectal cancer who regularly take low-dose aspirin experience a more favorable disease progression than patients who do not. This is particularly true of patients with a modified PI3K gene (PIK3CA mutation) in their tumor cells. In such patients, aspirin is believed to reduce the risk of a recurrence (relapse) after treatment for colorectal cancer. However, the results of current investigations into the role played by aspirin were compiled retrospectively and are somewhat equivocal. This is why the SAKK is now conducting its own study.
In the SAKK 41/13 trial, patients who have been treated for colorectal cancer and who are known to have a PIK3CA mutation will take aspirin or placebo every day for three years. They will be randomly assigned to the aspirin or placebo group, with two thirds of patients receiving aspirin and one third receiving placebo.